NCT02081963View on ClinicalTrials.gov

Combined Administration of Nebulized Amikacin in Patients With Acute Exacerbation of Non-Cystic Fibrosis Bronchiectasis

PHASE4CompletedINTERVENTIONAL
Enrollment

178

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

December 31, 2016

Conditions
Non-Cystic Fibrosis Bronchiectasis
Interventions
DRUG

Amikacin

Nebulized 0.2g of amikacin and 2 mL of normal saline twice a day for 14 days in combination with standard treatment.

DRUG

Normal saline

Nebulized 3 mL of normal saline twice a day for 14 days in combination with standard treatment.

Trial Locations (1)

250012

Qilu Hospital of Shandong University, Jinan

All Listed Sponsors
lead

Qilu Hospital of Shandong University

OTHER

NCT02081963 - Combined Administration of Nebulized Amikacin in Patients With Acute Exacerbation of Non-Cystic Fibrosis Bronchiectasis | Biotech Hunter | Biotech Hunter